Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Pemetrexed for Second-Line Pancreas Cancer

This study has been terminated.
(At interim analysis the study did not meet the response criteria to continue)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
Georgetown University
ClinicalTrials.gov Identifier:
NCT00864513
First received: March 17, 2009
Last updated: March 23, 2011
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2009
  Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)